DB:NPR1

Stock Analysis Report

Executive Summary

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has INSYS Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NPR1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

137.5%

NPR1

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

-98.1%

NPR1

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: NPR1 underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: NPR1 underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

NPR1IndustryMarket
7 Day137.5%-4.1%-5.7%
30 Day52.0%-8.2%-5.7%
90 Day-34.4%-2.0%-3.6%
1 Year-98.1%-98.1%4.0%3.7%9.3%6.1%
3 Year-99.2%-99.2%38.2%36.7%8.9%-0.7%
5 Year-99.6%-99.6%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is INSYS Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is INSYS Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether INSYS Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as INSYS Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is INSYS Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as INSYS Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has INSYS Therapeutics performed over the past 5 years?

-69.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NPR1 is currently unprofitable.

Growing Profit Margin: NPR1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NPR1 is unprofitable, and losses have increased over the past 5 years at a rate of -69.1% per year.

Accelerating Growth: Unable to compare NPR1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NPR1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: NPR1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is INSYS Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: NPR1 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NPR1 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NPR1 is debt free.

Reducing Debt: NPR1's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: NPR1 has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if NPR1's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if NPR1 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NPR1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is INSYS Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate NPR1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NPR1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NPR1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NPR1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NPR1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

INSYS Therapeutics has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Andrece Housley
Chief Financial Officer0.8yrsno data0.028% $1.4k
Venkat Goskonda
Chief Scientific Officer0.8yrsno datano data
Brian Jennings
Vice President of Sales2.6yrsno datano data

0.8yrs

Average Tenure

Experienced Management: NPR1's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
John McKenna
Chairman0yrsno datano data
Rohit Vishnoi
Independent Director2.7yrsUS$259.55k0.0053% $269.6
Vaseem Mahboob
Independent Director2yrsUS$271.53kno data
Trudy Vanhove
Independent Director1.8yrsUS$152.75kno data
Elizabeth Bohlen
Independent Director1.4yrsUS$145.24kno data

1.9yrs

Average Tenure

51yo

Average Age

Experienced Board: NPR1's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

INSYS Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: INSYS Therapeutics, Inc.
  • Ticker: NPR1
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.694m
  • Listing Market Cap: US$5.115m
  • Shares outstanding: 75.92m
  • Website: https://www.insysrx.com

Number of Employees


Location

  • INSYS Therapeutics, Inc.
  • 1333 South Spectrum Boulevard
  • Suite 100
  • Chandler
  • Arizona
  • 85286
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INSY.QOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2010
NPR1DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2010
0JBSLSE (London Stock Exchange)YesCommon StockGBUSDNov 2010

Biography

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. On June 10, 2019, INSYS Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/16 21:56
End of Day Share Price2020/01/16 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.